Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Clin Genitourin Cancer. 2015 May 16;13(5):453–460. doi: 10.1016/j.clgc.2015.05.003

Table 4. Common Toxicities during High-Dose TIC by Cohort in Phase I.

Cohort 1 (n=3) Cohort 2 (n=3) Cohort 3 (n=3) Cohort 4 (n=3) Cohort 5 (n=6) Total (n=18)
Toxicity G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3/4
Leukocytopenia 3 3 3 3 6 18
Lymphopenia 2 1 1 2 3 1 2 1 5 18
Neutropenia 3 3 3 3 6 18
Thrombocytopenia 3 3 3 3 6 18
Anemia 3 2 1 2 2 1 4 2 17
Hypophosphatemia 1 3 1 1 2 1 3 1 13
Hypokalemia 2 1 1 1 2 1 1 3 1 13
Elevated ALT 2 1 1 5 9
Febrile neutropenia 2 2 1 2 7
Hyperglycemia 1 1 1 1 3 7
Hyponatremia 1 1 2 3 7
Elevated Lipase 1 2 3
Elevated AST 2 2
Dyspnea 1 1 2
Fatigue 1 1 2
Hypotension 1 1 2
Elevated Creatinine 1 1 2

Abbreviations: TIC, paclitaxel, ifosfamide, and carboplatin; G = grade; ALT = alanine aminotransferase; AST, aspartate aminotransferase